Together, these data identify G6B as a promising cell surface antigen worthy of further validation as enabling selective targeting of aberrant megakaryocytic differentiation and mutant clone-derived HSPCs in myelofibrosis. This evidence concerns the gene MPIG6B and myelofibrosis.